Table 5.

Result of type of DR subgroup analysis of eNOS (4b/4a) polymorphism and DR risk in T2DM patients.

Variables	N	References	Case/control	Genetic model	Fixed-effects model		Random-effects model		Heterogeneity
					OR (95%CI)	p Value	OR (95%CI)	p Value	PH	I2 (%)
Type of DR				Allelic model
PDR	8	[10,11,19,23,28,37,41,42]	678/1670		0.822(0.697–0.970)	.021	1.036(0.738–1.454)	.837	0.001	70.6%
NPDR	8	[10,11,19,23,28,37,41,42]	1358/1670		1.001(0.879–1.140)	.990	0.970(0.792–1.188)	.770	0.072	44.5%
PDR	8	[10,11,19,23,28,37,41,42]	678/1670	Recessive model	1.427(0.922–2.211)	.111	1.086(0.556–2.119)	.809	0.133	35.7%
NPDR	8	[10,11,19,23,28,37,41,42]	1358/1670		0.881(0.643–1.205)	.448	0.873(0.633–1.203)	.406	0.700	0.0%
PDR	8	[10,11,19,23,28,37,41,42]	678/1670	Dominant model	0.822(0.675–1.001)	.052	1.022(0.699–1.493)	.912	0.002	67.3%
NPDR	8	[10,11,19,23,28,37,41,42]	1358/1670		0.970(0.826–1.139)	.712	0.953(0.763–1.191)	.672	0.125	36.7%
PDR	8	[10,11,19,23,28,37,41,42]	678/1670	Additive model	1.125(0.918–1.379)	.257	0.982(0.716–1.346)	.908	0.045	49.4%
NPDR	8	[10,11,19,23,28,37,41,42]	1358/1670		1.066(0.905–1.255)	.445	1.065(0.866–1.311)	.549	0.208	26.5%
PDR	8	[10,11,19,23,28,37,41,42]	678/1670	Homozygote model	0.611(0.392–0.951)	.029	0.947(0.432–2.076)	.891	0.042	50.2%
NPDR	8	[10,11,19,23,28,37,41,42]	1358/1670		1.123(0.809–1.559)	.487	1.134(0.810–1.588)	.463	0.667	0.0%
PDR	8	[10,11,19,23,28,37,41,42]	678/1670	Heterozygote model	0.848(0.690–1.042)	.116	1.017(0.710–1.456)	.928	0.011	59.8%
NPDR	8	[10,11,19,23,28,37,41,42]	1358/1670		0.953(0.806–1.127)	.572	0.949(0.765–1.177)	.634	0.193	28.2%

Note: PDR: Proliferative diabetic retinopathy; NPDR: Non-proliferative diabetic retinopathy; N: number of studies; OR: odd ratio; 95%CI: 95% confidence interval.